Compare MXL & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXL | DAWN |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2009 | 2021 |
| Metric | MXL | DAWN |
|---|---|---|
| Price | $17.84 | $10.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $19.80 | ★ $27.11 |
| AVG Volume (30 Days) | 998.2K | ★ 1.8M |
| Earning Date | 04-29-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $478,596,000.00 | $158,182,000.00 |
| Revenue This Year | $22.10 | $47.48 |
| Revenue Next Year | $10.70 | $31.10 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 20.60 |
| 52 Week Low | $8.40 | $5.64 |
| 52 Week High | $20.82 | $13.20 |
| Indicator | MXL | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 47.13 | 42.37 |
| Support Level | $17.90 | $10.07 |
| Resistance Level | $18.44 | $10.68 |
| Average True Range (ATR) | 0.95 | 0.64 |
| MACD | -0.13 | -0.20 |
| Stochastic Oscillator | 30.28 | 9.56 |
MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.